Sociedad Cientifica de San Fernando, Lima, Peru.
Red de Eficacia Clinica y Sanitaria (REDECS), Lima, Peru.
PLoS One. 2023 Feb 9;18(2):e0281064. doi: 10.1371/journal.pone.0281064. eCollection 2023.
Recently, the neutrophil-lymphocyte ratio (NLR) has become a biomarker for assessing inflammatory stress and prognosis in different diseases.
We aimed to conduct a systematic review and meta-analysis to summarize the current evidence on the capacity of the NLR to serve as a biomarker in neuromyelitis optica spectrum disorder (NMOSD).
Through a comprehensive systematic search up to December 2021 and using the search terms "neutrophil-to-lymphocyte ratio" and "neuromyelitis optica spectrum disorder" we selected studies evaluating NLR values in NMOSD patients. A meta-analysis was planned, and a narrative synthesis was performed when this was not possible. Subgroup and sensitivity analyses were planned. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach was used to assess certainty of the evidence.
Six studies were included (1036 patients). A significant increase in the NLR was observed between NMOSD patients and healthy controls with high heterogeneity (MD: 1.04; 95% CI: 0.76; 1.32; I2 = 59%). Regarding NMOSD prognosis, relapse (OR: 1.33 -OR: 2.14) was evaluated as being related to NLR with low certainty. An association with Expanded Disability Status Scale (EDSS) score ≥4 (OR: 1.23 -OR: 1.43) was reported with moderate certainty. An association with the occurrence of lesions on MRI was reported with an OR of 1.52.
We found the NLR to be useful as a biomarker of NMOSD as it was significantly increased in the patient group compared to the healthy control group with high certainty. Additionally, the NLR was applicable as an indicator of poor prognosis with low to moderate certainty.
最近,中性粒细胞与淋巴细胞比值(NLR)已成为评估不同疾病炎症应激和预后的生物标志物。
我们旨在进行系统评价和荟萃分析,以总结 NLR 作为视神经脊髓炎谱系疾病(NMOSD)生物标志物的现有证据。
通过全面系统搜索,截至 2021 年 12 月,使用“中性粒细胞与淋巴细胞比值”和“视神经脊髓炎谱系疾病”等检索词,我们选择了评估 NMOSD 患者 NLR 值的研究。计划进行荟萃分析,并在不可能的情况下进行叙述性综合。计划进行亚组和敏感性分析。使用推荐评估、制定与评价分级(GRADE)方法评估证据的确定性。
纳入了 6 项研究(1036 例患者)。NMOSD 患者与健康对照组之间的 NLR 显著增加,且具有高度异质性(MD:1.04;95%CI:0.76;1.32;I2=59%)。关于 NMOSD 预后,复发(OR:1.33-OR:2.14)被评估为与 NLR 相关,证据确定性为低。与扩展残疾状态量表(EDSS)评分≥4(OR:1.23-OR:1.43)相关的报道具有中度确定性。有报道称与 MRI 上病变的发生有关,OR 为 1.52。
我们发现 NLR 作为 NMOSD 的生物标志物具有较高的确定性,因为它在患者组中显著高于健康对照组。此外,NLR 作为不良预后的指标具有低至中度的确定性。